Get your patient on Rybelsus (Oral Semaglutide)

Rybelsus Savings Card, Coupon & Coverage 2026

>80%
of the top 10 commercial plans cover Rybelsus
69%
of plans require PA
$25/mo
with Rybelsus Savings Card
1
savings & assistance programs
Compare GLP-1 Alternatives
See how Rybelsus stacks up on access, cost, and PA burden — the factors that affect whether your patient can actually get on therapy.
Access MetricRybelsusOral Semaglutidezepboundmounjarowegovyozempic
Plan Coverage% of commercial plans>80%Best
PA Required% of plans requiring PA69%
Copay w/ SavingsWith manufacturer card
$25
Savings ProgramsTotal available1Most
Copay
Approved IndicationsFDA-approved uses
Type 2 DiabetesCardiovascular Risk
Get better comparisons with Prescriber.AI
See which alternative has the best coverage, lowest PA burden, and best savings for your patient's specific insurance.
See all comparisons →

Insurance Coverage

See specific coverage requirements for your patient's insurance plan.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
UnitedHealthcare (UHC)Rybelsus
Covered on 4 commercial plans
PA (4/4) · Step therapy (0/4) · Qty limit (4/4)
View full coverage details
Aetna HealthRybelsus
Covered on 5 commercial plans
PA (1/5) · Step therapy (1/5) · Qty limit (1/5)
View full coverage details
CIGNARybelsus
Covered on 4 commercial plans
PA (4/4) · Step therapy (0/4) · Qty limit (4/4)
View full coverage details
Coverage data sourced from MMIT. Updated monthly.

Savings & Copay Programs

Help your patients reduce out-of-pocket costs for Rybelsus.
$25/month
COPAY CARD
Rybelsus Savings CardEligible commercially-insured patients may pay as little as $25/month. Check program terms and enrollment eligibility.

Prior Authorization69% of plans require PA6 forms
Download the right PA form for your patient's insurance plan.

Most recent Rybelsus prior authorization forms

Aetna - Louisiania Prior Authorization Request FormUpdated May 11, 2026
Aetna - Medical Exception/Prior Authorization/Precertification Request for Prescription MedicationsUpdated May 11, 2026
Humana - General Prior Authorization FormUpdated May 11, 2026
Independence Health - Select Formulary Prior Authorization Form Updated May 11, 2026
Kaiser Permanente of Colorado - Medicare Medication Request form (MRF)Colorado · Updated May 11, 2026
View all PA forms for Rybelsus
Brand Resources
Formulary InformationFormulary Information resource
onehub-banner
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Prescribing Information
Indications
  • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.
Dosing Titration
3
3 mgFirst 30 daysTitration
7
7 mgAfter 30 daysMaintenance
14
14 mg≥30 days laterMax dose
Oral tablet · once daily · empty stomach with ≤4 oz water, ≥30 min before first food/beverage/other oral medication. 3 mg is for initiation only and not effective for glycemic control. Maximum: 14 mg once daily.
Common Side Effects
Nausea
20%
Abdominal Pain
11%
Diarrhea
10%
Decreased appetite
9%
Vomiting
8%
Contraindications
  • A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in RYBELSUS or OZEMPIC tablets. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with semaglutide tablets.
Full FDA Prescribing Information
Access the complete FDA-approved prescribing label for Rybelsus, including approved indications, recommended dosage & administration schedules, contraindications, warnings & precautions, adverse reactions, drug interactions, and use in specific populations.

Resources

Dosage & administration

DOSAGE AND ADMINISTRATION

  • RYBELSUS and OZEMPIC tablets are not substitutable on a mg-to-mg basis.
  • Take RYBELSUS or OZEMPIC tablets orally once daily on an empty stomach in the morning with water (up to 4 ounces of water); do not take with other liquids besides water. (2.1 )
  • Swallow tablets whole. Do not split, crush, chew or dissolve in any solution. (2.1 )
  • After taking RYBELSUS or OZEMPIC tablets, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications. (2.1 )
  • See the Full Prescribing Information for instructions on switching between RYBELSUS and OZEMPIC tablets (2.3 ) and from OZEMPIC injections to RYBELSUS or OZEMPIC tablets. (2.4 )

Recommended Starting, Escalation and Maintenance Dosage of RYBELSUS and OZEMPIC Tablets (2.2 )

RYBELSUS (2.2 )

  • Day 1 to 30: Recommended starting dosage is 3 mg orally once daily for 30 days (this dosage is not effective for glycemic control)
  • Days 31 to 60: Increase the dosage to 7 mg orally once daily.
  • On Day 61 or thereafter, if: (2.2 )
  • No additional glycemic control is needed, maintain the dosage at 7 mg orally once daily.
  • Additional glycemic control is needed, increase the dosage to 14 mg orally once daily.

OZEMPIC Tablets (2.2 )

  • Day 1 to 30: Recommended starting dosage is 1.5 mg orally once daily for 30 days (this dosage is not effective for glycemic control).
  • Days 31 to 60: Increase the dosage to 4 mg orally once daily.
  • On Day 61 or thereafter, if: (2.2 )
  • No additional glycemic control is needed, maintain the dosage at 4 mg orally once daily.
  • Additional glycemic control is needed, increase the dosage to 9 mg orally once daily.

Important Administration Instructions

  • RYBELSUS and OZEMPIC tablets are not substitutable on a mg-to-mg basis.
  • Take one RYBELSUS or OZEMPIC tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces of water). Do not take RYBELSUS or OZEMPIC tablets with other liquids besides water [see Clinical Pharmacology (12.3 )] .
  • Do not take more than one tablet per day.
  • Swallow tablets whole. Do not split, crush, chew or dissolve in any solution.
  • After taking RYBELSUS or OZEMPIC tablets, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications [see Clinical Pharmacology (12.3 )] .
  • If a dose is missed, skip the missed dose and take the next dose the following day.

Recommended Starting, Escalation and Maintenance Dosage of RYBELSUS and OZEMPIC Tablets

RYBELSUS: Recommended Dosage

Follow the RYBELSUS starting, escalation, and maintenance dosage described below to reduce the risk of gastrointestinal (GI) adverse reactions [see Warnings and Precautions (5.6 ), Adverse Reactions (6.1 )] :

  • Starting Dosage (Initiation Phase) (Days 1 to 30) : The recommended starting dosage is 3 mg orally once daily (this dosage is not effective for glycemic control).
  • Escalation and Maintenance Dosage (Days 31 and beyond) :
  • Days 31 to 60: Increase the dosage to 7 mg orally once daily.
  • On Day 61 or thereafter, if:
  • No additional glycemic control is needed, maintain the dosage at 7 mg orally once daily.
  • Additional glycemic control is needed, increase the dosage to 14 mg orally once daily.

OZEMPIC Tablets: Recommended Dosage

Follow the OZEMPIC tablets starting, escalation, and maintenance dosage described below to reduce the risk of GI adverse reactions [see Warnings and Precautions (5.6 ), Adverse Reactions (6.1 )] :

  • Starting Dosage (Initiation Phase) (Days 1 through 30) : The recommended starting dosage is 1.5 mg orally once daily (this dosage is not effective for glycemic control).
  • Escalation and Maintenance Dosage (Days 31 and beyond) :
  • Days 31 to 60: Increase the dosage to 4 mg orally once daily.
  • On Day 61 or thereafter, if:
  • No additional glycemic control is needed, maintain the dosage at 4 mg orally once daily.
  • Additional glycemic control is needed, increase the dosage to 9 mg orally once daily.

Switching Between RYBELSUS and OZEMPIC Tablets

  • Do not switch between RYBELSUS and OZEMPIC tablets during the initiation phase (Days 1 to 30) [see Dosage and Administration (2.2 )] .
  • After 30 days of RYBELSUS or OZEMPIC tablet treatment (after the initiation phase) [see Dosage and Administration (2.2 )] , patients may switch between RYBELSUS and OZEMPIC tablet products (see Table 1 ).
  • When switching between RYBELSUS and OZEMPIC tablets, initiate the other semaglutide tablet product the day after discontinuing the previous semaglutide tablet product.

Table 1. Switching Between Escalation or Maintenance Dosage of RYBELSUS and OZEMPIC Tablets

RYBELSUS

OZEMPIC Tablets

7 mg orally once daily

4 mg orally once daily

14 mg orally once daily

9 mg orally once daily

Switching from OZEMPIC Injection to RYBELSUS or OZEMPIC Tablets

Switching from OZEMPIC Injection to RYBELSUS Tablets

  • Patients taking the 0.5 mg dose of OZEMPIC injection may switch to RYBELSUS tablets.
  • One week after discontinuing 0.5 mg of subcutaneous OZEMPIC injection, start 7 mg or 14 mg of RYBELSUS orally once daily.

Switching from OZEMPIC Injection to OZEMPIC Tablets

  • Patients taking the 0.5 mg dose of OZEMPIC injection may switch to OZEMPIC tablets.
  • One week after discontinuing 0.5 mg of subcutaneous OZEMPIC injection, start 4 mg or 9 mg of OZEMPIC tablets orally once daily.

PubMed™ news

5 most recent articles for Rybelsus , view all articles on PubMed™
Show the latest PubMed™ articles for Rybelsus

Frequently Asked Questions